Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Elastic NV (ESTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Elastic NV — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Elastic NV trades at $60.1 (market cap $6.18B). The key difference: Elastic NV is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Elastic NV nearer its low. Which is the better fit depends on your goals.
| ACAD | ESTC | |
|---|---|---|
Market Cap | $4.49B | $6.18B |
Sector | Health | Technology |
52-Week High | $28.06 | $94.47 |
52-Week Low | $20.06 | $43.30 |
Enterprise Value | $3.69B | $5.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Elastic (ESTC) trades at $58.54, up 0.86% with neutral technical signals. The company shows strong profitability metrics including 76% gross margins and 21% net income margin projected for 2026, though 2025 results showed a net loss. Recent earnings beats and positive analyst sentiment (67% buy ratings) support the stock, with a $72.80 consensus price target representing 24% upside potential.
ESTC presents a growth opportunity with improving financials and market leadership in search AI, though risks include ongoing legal investigations and competitive pressures. The stock's current valuation appears reasonable relative to growth prospects, with technical indicators suggesting consolidation near key support at $57.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →
